177 Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma

• Natalia Kirillova,
• Robert Hawkins,
• Gray Kueberuwa,
• Paul C Lorigan,
• Yizhou Jiang,
• Fiona C Thistlethwaite,
• Manon Pillai,
• Martine Thomas,
• John S Bridgeman,
• Ryan D Guest,
• Zachary J Roberts

Affiliations

Natalia Kirillova

Aff2 grid.498124.2Cellular Therapeutics Limited Manchester United Kingdom

Robert Hawkins

Aff1 grid.412917.80000000404309259Department of Medical OncologyChristie NHS Foundation Trust Manchester United Kingdom

Gray Kueberuwa

Aff1 0000000121662407grid.5379.8Clinical and Experimental Immunotherapy Group, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Division of Cancer SciencesThe University of Manchester Wilmslow Road, Withington M20 4QL Manchester UK

Paul C Lorigan

Division of Cancer Sciences, The University of Manchester, Manchester, UK

Yizhou Jiang

2Instil Bio, Inc., Dallas, TX, USA

Fiona C Thistlethwaite

4The Christie, NHS Foundation Trust, Manchester, UK and University of Manchester, Manchester, UK

Manon Pillai

3The Christie, NHS Foundation Trust, Manchester, UK

Martine Thomas

2Instil Bio, Inc., Dallas, TX, USA

John S Bridgeman

2Instil Bio, Inc., Dallas, TX, USA

Ryan D Guest

2Instil Bio, Inc., Dallas, TX, USA

Zachary J Roberts

2Instil Bio, Inc., Dallas, TX, USA